SCHEMBL14549935

C[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CS)NC(=O)[C@H](CS)NC(=O)C(Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)C(CS)NC(=O)[C@H](CS)NCC=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O

nearest known ligand 0.51

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	OPRM1	P35372	3/20	0.51

▸	OPRD1	P41143	3/20	0.51

▸	OPRK1	P41145	2/20	0.51

▸	CALCR	P30988	5/20	0.49

▸	RAMP3	O60896	1/20	0.49

▸	MAPK8	P45983	1/20	0.49

▸	MAPK9	P45984	1/20	0.49

▸	MAPK10	P53779	1/20	0.49

▸	KEAP1	Q14145	2/20	0.49

▸	HCRTR1	O43613	1/20	0.48

▸	HCRTR2	O43614	1/20	0.48

▸	SLC6A2	P23975	1/20	0.48

▸	NTSR1	P30989	1/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL16352049	0.93	KEAP1 (0.54)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL30163225	0.93	KEAP1 (0.54)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL28210612	0.92	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL14549930	0.92	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL30163263	0.92	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL15130591	0.92	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL28846618	0.92	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL30163405	0.92	OPRM1 (0.56)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL30163248	0.91	OPRM1 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3
SCHEMBL30353299	0.91	SLC6A2 (0.55)	OPRM1OPRD1OPRK1CALCRRAMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20130012454-A1	Orally Disintegrating Compositions of Linaclotide	IRONWOOD PHARMACEUTICALS, INC. (US)	2013-01-10	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130012454-A1	Orally Disintegrating Compositions of Linaclotide	LPXN, SI, CEL	OPRM1 1645/4885OPRD1 816/4885OPRK1 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.